New combo therapy shows promise for tough lung cancer mutations
NCT ID NCT04695925
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 27 times
Summary
This study compares a standard targeted therapy (osimertinib) alone versus the same drug plus chemotherapy for people with advanced non-small cell lung cancer that has both EGFR and TP53 gene mutations. About 294 participants will be randomly assigned to one of the two treatments to see which works better at delaying cancer growth. The goal is to find a more effective first-line treatment for this specific group of patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Central Hospital of Guangdong Nongken, Zhanjiang Cancer Hospital
Zhanjiang, China
-
Department of Medical Oncology,Cancer Center of Sun Yat-Sen University
Guangzhou, Guangdong, 510060, China
Conditions
Explore the condition pages connected to this study.